The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer

The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer

CRC is one of the leading causes of cancer mortality worldwide. Chemotherapy is widely used for the treatment of CRC, but its efficacy remains unsatisfactory, mainly due to drug resistance. Therefore, it is urgent to develop new strategies to overcome drug resistance. Combination therapy that aims t...

Full description

Bibliographic Details
Main Authors: Bo Kang, Xiaobing Zhang, Weibing Wang, Shiqi She, Wenjie Chen, Cheng Chen, Yisha Wang, Xiaoyun Pan, Ouyuan Xu, Yingjie Wang
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
colorectal cancer
IGF-1R
PB-020
MBZ
PD-1
combination therapy
Online Access:https://www.mdpi.com/2072-6694/14/23/5747

Internet

https://www.mdpi.com/2072-6694/14/23/5747

Similar Items